Conference
The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.
Abstract
TPS12144
Background: Patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive curative chemoradiation (CRT) with Cisplatin, as a standard of care. A meta-analysis of 52 randomized trials comparing Low Dose (LD) and High Dose (HD) schedules demonstrated differing toxicity profiles but hearing effects were not rigorously studied. Hearing loss associated with HD Cisplatin can result in …
Authors
Kuruvilla S; Meyers BM; Parker C; Nichols AC; Smoragiewicz M; Hotte SJ; Pond GR; Louie AV; Stewart P; Black M
Volume
40
Pagination
pp. tps12144-tps12144
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2022
DOI
10.1200/jco.2022.40.16_suppl.tps12144
Conference proceedings
Journal of Clinical Oncology
Issue
16_suppl
ISSN
0732-183X